The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

May. 17, 2017
Applicant:

Duke University, Durham, NC (US);

Inventors:

Andrew Nixon, Durham, NC (US);

Chris Brady, Durham, NC (US);

Yingmiao Liu, Durham, NC (US);

Herbert Hurwitz, Durham, NC (US);

Kouros Owzar, Durham, NC (US);

Alexander Sibley, Durham, NC (US);

Chen Jiang, Durham, NC (US);

Ace Hatch, Durham, NC (US);

Mark Starr, Durham, NC (US);

Assignee:

Duke University, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); G01N 33/574 (2006.01); C07K 16/22 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); C12Q 1/6886 (2018.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57419 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided. The methods may include obtaining a sample from the subject, determining an expression level of at least one biomarker selected from the group consisting of VEGF-D and PlGF in a sample from the subject, comparing the expression level of the biomarker in the sample to a reference level of the biomarker, and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. Optionally, the methods may further include administering a VEGF target agent and/or an anticancer or chemotherapy agent to the subject. Additional methods of prognosing and treating a cancer in a subject are also provided.


Find Patent Forward Citations

Loading…